ArticleHemaSphere2022
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report.
Abstract read
In one paragraph
Article in HemaSphere, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- 30 years in service, 1996-2026: Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).Annals of hematology · 2026Review
- Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry.Open forum infectious diseases · 2026Article
- Vaccination of patients with hematological malignancies: barriers and strategies to improve uptake.Frontiers in medicine · 2026Review
- Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report.American journal of hematology · 2025Article
- Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals.Advances in therapy · 2025Review
- Multi-center study of COVID-19 infection in elderly patients with lymphoma: on behalf of Jiangsu Cooperative Lymphoma Group (JCLG).Annals of hematology · 2024Article
- [Single-center study of COVID-19 in patients with chronic lymphocytic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey.Infection · 2024Article
- Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.EClinicalMedicine · 2024Article
- Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases.Annals of hematology · 2024Article
- Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy.Transplant infectious disease : an official journal of the Transplantation Society · 2023Review
- Evolution of Humoral and Cellular Immunity Post-Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab.Open forum infectious diseases · 2023Article
- Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease.Blood cancer journal · 2023Article
- COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.The Journal of infectious diseases · 2023Review
- COVID-19 infection among patients with cancer in Australia from 2020 to 2022: a national multicentre cohort study.The Lancet regional health. Western Pacific · 2023Article
- Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey.Blood advances · 2023Article
- Review
- COVID-19 in Adult Patients with Hematological Malignancies-Lessons Learned after Three Years of Pandemic.Biology · 2023Review
- Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.Journal of hematology & oncology · 2023Article
- [Chinese consensus on severe acute respiratory syndrome coronavirus-2 vaccination in adult patients with hematological diseases (2023)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Jon Salmanton-GarcíaUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Germany.
Francesco MarchesiHematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Andreas GlenthøjDepartment of Hematology, Copenhagen University Hospital-Rigshospitalet, Denmark.
Yavuz M BilginDepartment of Internal Medicine, ADRZ, Goes, the Netherlands.
Jens van PraetDepartment of Nephrology and Infectious diseases, AZ Sint-Jan Brugge-Oostende AV, Belgium.
Julio Dávila-VallsHospital Nuestra Señora de Sonsoles, Ávila, Spain.
Sonia Martín-PérezHospital Nuestra Señora de Sonsoles, Ávila, Spain.
Jorge LabradorDepartment of Hematology, Research Unit, Hospital Universitario de Burgos, Spain.
Jaap van DoesumUniversity Medical Center Groningen, the Netherlands.
Iker Falces-RomeroLa Paz University Hospital, Madrid, Spain.
Francesca FarinaIRCCS Ospedale San Raffaele, Milan, Italy.
Martin SchönleinDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Germany.
Mathilde ChanutCentre Hospitalier de Versailles, Le Chesnay, Université Paris-Saclay, UVSQ, Inserm, Équipe "Exposome et Hérédité", CESP, Villejuif, France.
Verena PetzerIRCCS Ospedale San Raffaele, Milan, Italy.
Ildefonso EspigadoDepartment of Hematology, University Hospital Virgen Macarena-University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/ CSIC), Universidad de Sevilla (Departamento de Medicina), Spain.
Michelina DargenioHematology and Stem Cell Transplant Unit, Vito Fazzi, Lecce, Italy.
Avinash AujayebNorthumbria Healthcare, Newcastle, United Kingdom.
Uluhan SiliMarmara University, Istanbul, Turkey.
Laura SerranoHospital Universitario de Cabueñes, Gijón, Spain.
László Imre PinczésDivision of Hematology, Department of Internal Medicine, University of Debrecen, Hungary.
Nick de JongeAmsterdam UMC, Location VUmc, Amsterdam, the Netherlands.
Andrés Soto-SilvaFaculty of Medicine, University of Chile. Infectious Diseases Unity, Salvador Hospital of Santiago, Santiago de Chile, Chile.
Caterina BuquicchioEmatologia con Trapianto, Ospedale Dimiccoli Barletta, Italy.
Lucia PreziosoHospital University of Parma - Hematology and Bone Marrow Unit, Parma, Italy.
Monia MarchettiAzienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Stef MeersAZ KLINA, Brasschaat, Belgium.
Alessandro BuscaStem Cell Transplant Center, AOU Citta' della Salute e della Scienza, Turin, Italy.
Paolo CorradiniUniversity of Milan and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Martin HoeniglDivision of Infectious Diseases and Global Public Health, Department of Medicine, Clinical and Translational Fungal-Working Group, University of California San Diego, CA, USA.
Philipp KoehlerUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Germany.
Laman RahimliUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Germany.
Gökçe Melis ÇolakMarmara University, Istanbul, Turkey.
Elena ArellanoDepartment of Hematology, University Hospital Virgen Macarena, Seville, Spain.
Dominik WolfIRCCS Ospedale San Raffaele, Milan, Italy.
Stefanie GräfeUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Germany.
Emanuele AmmatunaUniversity Medical Center Groningen, the Netherlands.
Caroline Berg VenemyrDepartment of Hematology, Copenhagen University Hospital-Rigshospitalet, Denmark.
Oliver A CornelyUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Germany.
Livio PaganoHematology Unit, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.